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Therapeutic resistance remains a major cause of cancer-related deaths. Resistance can
occur from the outset of treatment or as an acquired phenomenon after an initial clini-
cal response. Therapeutic resistance is an almost universal phenomenon in the treatment
of metastatic cancers.The advent of molecularly targeted treatments brought greater efﬁ-
cacy in patients whose tumors express a particular target or molecular signature. However,
resistance remains a predictable challenge. This article provides an overview of somatic
genomic events that confer resistance to cancer therapies. Some examples, including
BCR–Abl, EML4–ALK, and the androgen receptor, contain mutations in the target itself,
which hamper binding and inhibitory functions of therapeutic agents.There are also exam-
ples of somatic genetic changes in other genes or pathways that result in resistance by
circumventing the inhibitor, as in resistance to trastuzumab and BRAF inhibitors. Yet other
examples results in activation of cytoprotective genes. The fact that all of these mecha-
nisms of resistance are due to somatic changes in the tumor’s genome makes targeting
them selectively a feasible goal. To identify and validate these changes, it is important
to obtain biopsies of clinically resistant tumors. A rational consequence of this evolving
knowledge is the growing appreciation that combinations of inhibitors will be needed to
anticipate and overcome therapeutic resistance.
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The fundamental challenge in all anti-cancer therapeutics is resis-
tance. This is true of all forms of therapy, in early disease and in
advanced metastatic cancers. It may be reﬂected as either intrinsic
or acquired therapeutic resistance.While the problemwith regards
to classical cytotoxic treatments has been studied for decades in
various experimental models, few of the mechanisms or models
of resistance have been clearly shown to play a decisive role in the
clinical setting, and still fewer are amenable to manipulation in
order to overcome resistance.
The goal is to identify what are often multiple mechanisms of
resistance in a detection system with “clinical utility.” Notwith-
standing gene expression assays and protein-based studies, DNA-
based tests remain the most robust. Indeed inter-observer and
inter-platform variability appear to be much greater problems
with the former two technologies (Press et al., 2005; Mackay et al.,
2011). Identifying mutations and generating multiplexed assays is
a very realistic goal for clinically useful tools. However, to date few
somatic genetic events have been conﬁrmed in clinical samples as
drivers of therapeutic resistance,mostly due to the dearth of tissue
samples from resistant tumors. This article provides a brief out-
line of the role of genomic mutations in therapeutic resistance to
“targeted” anti-cancer therapies.
The advent of targeted agents generates much enthusiasm
because of enhanced efﬁcacy and reduced toxicity, yet therapeutic
resistance remains a core challenge. For instance,amongst themost
startling targeted agents of the recent decade is the small molecule
kinase inhibitor Imatinib (Gleevec), which targets the BCR–Abl
fusion gene that drives chronic myelogenous leukemia. This drug
binds and inhibits the oncogene’s growth promoting function,
and was so effective that it moved to regulatory approval and the
clinic in unprecedented time. The target was clear, and thus the
inevitable resistance was predictably the result of somatic muta-
tions in the target, the kinase domain of BCR–Abl (Shah et al.,
2002). A fairly restricted number of mutations are responsible for
conformational changes in the target, and so medicinal chemists
devised new chemical structures that became the next generations
of effective inhibitors (Hochhaus et al., 2007).
A second example of a druggable gene fusion somatic event,
and the ﬁrst in solid tumors, is the EML4–ALK gene fusion found
in 5% of non-small cell lung cancers (NSCLC). Crizotinib is a
small molecule ALK inhibitor which has showed excellent clinical
results in patients whose lung tumors carry the ALK gene fusion.
Similarly to the imatinib story, two recent reports have discovered
secondary mutations in the kinase domain of the ALK gene that
appear to be responsible for resistance to crizotinib and also to
two other unrelated ALK inhibitors (Choi et al., 2010; Sasaki et al.,
2011). Interestingly, both the site of one of the secondary muta-
tions in theALK kinase domain reported by Choi et al. (2010), and
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of secondary mutations found in the Abl kinase, are located at the
bottom of the ATP binding pockets of these respective kinases.
Mutations in the target are responsible for therapeutic resis-
tance in much older targeted agents as well, such as one of
the oldest such class of agents, the antiandrogens used to treat
prostate cancer. The proliferation and survival of prostate cancer
cells is critically dependent on androgen receptor (AR) signaling
axis (Balk, 2002; Culig et al., 2002). Androgen ablation therapy
is the current mainstay treatment for advanced prostate cancer.
This method aims to suppress AR activation by reducing testic-
ular androgen secretion via castration and/or by disrupting the
binding of androgens to AR using antiandrogens, such as ﬂu-
tamide, nilutamide, and bicalutamide. Despite initial response,
most patients progress to a lethal disease state called castration
resistant prostate cancer (CRPC; Taplin and Ho, 2001). To date,
the median survival time for patients with established CRPC is
<2 years (Petrylak et al., 2004; Tannock et al., 2004). Emerg-
ing biological observations in prostate cancer have indicated that
most CRPC cells are still dependent on the AR signaling for pro-
liferation and survival, and in CRPC cells, the AR is activated
by multiple mechanisms that cannot be effectively suppressed by
castration and currently clinically used antiandrogens (Agoulnik
and Weigel, 2006). In particular, mutations in AR render the AR
promiscuous so that it can be activated by a broad range of non-
androgen ligands, even antiandrogens (Krishnan et al., 2002). The
incidence of AR mutation in prostate cancer is estimated to be in
the range of 10–40% (Taplin et al., 2003; Miyamoto et al., 2004;
Taplin, 2008). A series of AR mutations, such as T877A, H874Y,
W741C,L701H, andV715Mwere identiﬁed from tissue specimens
of CRPCpatients, and found toproducemutatedARswhich canbe
activated by a series of non-androgen ligands (Chang et al., 2001;
Krishnan et al., 2002). In cellular models, the T877A and H874Y
mutated ARs are paradoxically activated by hydroxyﬂutamide, an
active metabolite of the anti-androgen drug ﬂutamide (Steke-
tee et al., 2002). The T877A mutant is activated by nilutamide
(Urushibara et al., 2007), and the W741C mutant is paradoxi-
cally activated by bicalutamide (Hara et al., 2003). Signiﬁcantly,
the T877A and W741C mutations were found in patients who
experienced treatment failure with ﬂutamide and bicalutamide,
respectively (Taplin et al., 2003). It appears that novel antiandro-
gens effective against the wild type AR and multiple mutated ARs
represent an attractive strategy for combating resistance to cur-
rently clinically used antiandrogens (Zhou et al., 2009). Other
novel anti-androgen therapies such as abiraterone, which target
androgen production in peripheral tissue, demonstrate signiﬁcant
clinical beneﬁts. This contributes to the case that there are likely
multiple mechanisms of resistance, but most importantly, that the
AR is still operational even CRPC patients (Ryan and Tindall,
2011).
It is likely a function of the importance of both BCR–Abl in
CML and AR in prostate cancer that mutations in these targets
themselves are themost commonmechanismsof therapeutic resis-
tance to these targeted therapeutic agents. There are, in contrast,
many other contexts in which the target of a clinically effective
therapy is known, and mutations of the target itself do not appear
to play a role in the development of resistance, although other
somatic genetic events appear to do so.
The antibody trastuzumab was developed to target HER2 over-
expressing breast cancer resulting from ampliﬁcation of the gene
(15%), and is effective in the adjuvant setting, and less so to
treat metastatic disease. It is always combined with cytotoxic
chemotherapy,which results in signiﬁcant efﬁcacy (Jackisch, 2006;
Bartsch et al., 2007). Therefore, early stage breast cancer patients
routinely have quantitative analysis of HER2 to guide the addition
of trastuzumab. The adjuvant use of trastuzumab plus chemother-
apy in breast cancer does not beneﬁt up to 15%of cases, suggesting
the presence of intrinsic resistance (Gianni et al., 2011). The bio-
logical implication is that HER2 ampliﬁcation is not a dominant
or driver modiﬁcation in these patients’ tumors.
Although many mechanisms of resistance to trastuzumab have
been discovered in pre-clinical models, including the activation
of downstream signaling pathways [AKT (Nahta and O’Regan,
2010), SRC (Zhang et al., 2011), PKA (Gu et al., 2009)], as well as
somatic genetic events such as the co-ampliﬁcation of oncogenes
(e.g., MYC), deletions in tumor suppressor genes (e.g., PTEN;
Christodoulou et al., 2009), mutations in components of HER
signaling (e.g., PIK3CA (Kataoka et al., 2010)), none of these have
yet passed the test of clinical validation. Indeed, there is signif-
icant doubt about the clinical existence of acquired resistance
to trastuzumab, underlying the current practice of continuing
trastuzumab while changing that cytotoxic chemotherapy given
in combination with it (Chang et al., 2001; Taplin et al., 2003;
Miyamoto et al., 2004; Taplin, 2008; Christodoulou et al., 2009; Gu
et al., 2009; Nahta and O’Regan, 2010; Zhang et al., 2011) upon
tumor progression. It may be more difﬁcult to overcome the effect
of multiple copies of the ERBB2 gene, as well as, perhaps, of genes
accompanying it on the 17q12–21 amplicon, than that of an acti-
vating mutation in a single oncogene. More recently, evidence has
emerged demonstrating a clinical beneﬁt of adding trastuzumab
to chemotherapy in the 10–15% of gastric carcinomas that have
ampliﬁcation of HER2 using FISH analysis (Fornaro et al., 2011).
While clinical responses are more frequent and durable in these
patients, they all do relapse, and the mechanism of resistance is
unknown.
Large scale sequencing of cancer genomes led to the discov-
ery of activating mutations in the serine threonine kinase BRAF
in patients with melanoma (Davies et al., 2002). A substitution
of glutamic acid for valine amino acid 600 (V600E) encompasses
90% of BRAF mutations and causes a 500-fold increase in activity
in comparison to the wild type protein (Wan et al., 2004). This
led to the development of novel mutant BRAF targeted therapies,
including RG7204/OR5185426 (Plexxikon/Roche), GSK2118236
(Glaxo Smith Kline), RAF265 (Novartis), and XL-281 (Bristol
Myers Squibb). These compounds are in clinical trials, and some
have already produced startling clinical response rates in compar-
ison to standard chemotherapy (Kefford et al., 2010; Chapman
et al., 2011; Sharfman et al., 2011). However, these responses are
short lived and patients relapse within 8–12months.
The mechanisms of BRAF inhibitor resistance can be intrinsic
or acquired, since not all patients respond,butmany responders do
relapse. Todate secondarymutations inBRAFhave not been found
in either pre-clinical or clinical samples of resistant melanomas.
In melanoma cells, constitutive BRAF/MEK/ERK signaling dri-
ves cell cycle entry and uncontrolled growth by increasing cyclin
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D1 expression. Pre-clinical data suggests that increased cyclin D1
expression can mediate BRAF inhibitor resistance in BRAFV600E
mutated melanomas (Smalley et al., 2008). This is of particu-
lar interest given the recent demonstration of the cyclin D1 is
involvement in DNA repair (Jirawatnotai et al., 2011) and that
cyclin D1 ampliﬁcation has been reported in as many as 32%
of primary melanomas, although its incidence may be less in
metastatic tumors (Lázár et al., 2009). Melanomas can also acquire
resistance through a variety of putative mechanisms, including
activation of alternative survival pathways via receptor and non-
receptor tyrosine kinases (such as PDGFRβ, IGF-1R, and COT),
RAS-mediated reactivation of the MAPK pathway and a switch in
signaling through other RAF isoforms (Johannessen et al., 2010;
Nazarian et al., 2010). A recent report also found that muta-
tions in NRAS may lead to acquired resistance to anti-BRAF
targeted agents (Nazarian et al., 2010). In one of 16 patients,
an NRAS mutation appeared after progression during treatment
with PLX4032, a BRAF inhibitor. The patient was continued on
therapy, and another lesion that subsequently appeared showed a
distinct NRAS mutation. Interestingly, both mutations were asso-
ciated with an increase in NRAS DNA copy number. The NRAS
gene is mutated in about 20% of primary melanomas (Lázár
et al., 2009), and apparently never simultaneously with a BRAF
mutation.
In a recent report by Villanueva et al. (2010) the acquisition of
BRAF inhibitor resistance led to a recovery of MAPK signaling and
was associatedwith an increase in CRAF protein expression (Mon-
tagut et al., 2008; Fedorenko et al., 2011). This ﬂexible switching
between RAF isoforms led to cross-resistance with other BRAF
inhibitors and was not associated with acquired secondary muta-
tions in BRAF,NRAS, or PTEN. In fact the RAF isoform switching
it not an example of a somatic genetic change associatedwith resis-
tance, but more likely a post-transcriptional change. This is a good
example of how studying therapeutic resistance to targeted agents
can provide opportunities to learn about biological functions.
These resistance pathways are potentially targetable. For exam-
ple, combining inhibitors of PI3K or IGF-1Rwith aMEK inhibitor
could overcome resistance in several BRAF refractory cells (Vil-
lanueva et al., 2010). Several studies have now identiﬁed BRAF
ampliﬁcation as a mechanism for MEK inhibitor resistance in
BRAF or K-RAS mutant cells and a recent study identiﬁed an acti-
vating mutation at codon 121 in the downstream kinase MEK1
which increased kinase activity and conferred robust resistance
to combined MEK/RAF inhibition. Interestingly, this mutation
that was absent in the corresponding pre-treatment tumor (Little
et al., 2011; Wagle et al., 2011). For patients with BRAF mutant
tumors, the results also provide a mechanistic basis for trials test-
ing concurrent treatment with both RAF and MEK inhibitors.
Such trials are currently accruing patients with BRAF mutant
metastatic melanoma (clinicaltrials.gov identiﬁers NCT01072175
and NCT01231594), and the results are eagerly awaited. In sum-
mary, new strategies are needed to treat patients with melanomas
carrying the BRAF V600E mutation in whom resistance to anti-
BRAF develops (Corcoran et al., 2010). These are mainly based on
the combined inhibition of MEK and RAF. But resistance that is
caused by mutations affecting RAS proteins may be more difﬁcult
to treat because attempts to develop direct inhibitors of RAS have
all met with failure. The combined inhibition of MEK and RAF
will not affect the activation of other RAS targets. Inhibitors of
MEK have also been found to have clinical activity in melanoma
and are nowbeing tested in patientswithBRAF inhibitor resistance
(Dummer et al., 2008; Infante et al., 2011).
The example of reversion of BRCA2 mutations is an unusual
and striking instance of a somatic genetic event underlying the
development of therapeutic resistance (Sakai et al., 2008). Sakai
et al. (2008) found that breast cancer and pancreatic cancer cell
lines carryingBRCA2mutations and that haddeveloped therapeu-
tic resistance to either cisplatin or the PARP inhibitor AG14361
were found to have re-activated BRCA2 through the develop-
ment of secondary intragenic mutations. Moreover, in two of ﬁve
patients with ovarian carcinoma whose tumors had become resis-
tant to cisplatin, genetic reversion to a normal BRCA2 allele was
found in one resistant tumor and selection for loss of the mutant
BRCA2 allele was found in another one. The authors speculated
that cisplatin treatment itself could enable secondary mutations
because of its DNA damaging effect. Another hypothesis is that
as BRCA2 is involved in DNA repair and homologous recombi-
nation, BRCA2 deﬁciency itself in these tumors may promote the
formation of secondary mutations.
EGF receptor (HER-1) represents another important target that
has been addressed therapeutically, since it is overexpressed in
a number of cancers and is associated with aggressive behavior,
advanced disease and resistance to standard therapies (Baselga and
Mendelsohn, 1997). Two different approaches have been taken,
and each has proven therapeutic efﬁcacy in distinct contexts:
(i) antibodies that effectively compete with the ligand binding
(Erbitux, Panitumumab), for the treatment of metastatic colorec-
tal cancer and regional head and neck cancer, (ii) small molecules
that compete for ATP binding in the kinase domain of the recep-
tor (erlotinib, geﬁtinib), with activity in a subset of patients with
NSCLC.
Mutations play interesting and distinct roles in these two con-
texts. In the case of the small molecules, genomic sequencing of
responding tumors demonstrated distinct mutations in the kinase
domain of the EGF receptor,most often in exons 19 and 21 (Lynch
et al., 2004; Paez et al., 2004). These mutations enhance ATP
binding, resulting in “addiction” of the tumor to EGFR-driven
phosphorylation,and enhanced sensitivity to the inhibitors.Hence
in this context mutations in the target signal enhanced sensitivity.
Yet, a distinct mutation has been demonstrated in clinically relaps-
ing tumors, which had initially responded to the small molecules
(Wu et al., 2008), and so the speciﬁcity of the mutations is critical
in this scenario.
The anti-EGFR antibodies present yet another scenario of ther-
apeutic resistance. The key initial ﬁnding was that an activating
mutation in a downstream protein in the EGFR signaling path-
way, in particular K-RAS, is associated with clinical resistance to
these antibodies targeting the ligand binding domain. In an inter-
esting exception, mutations in particular domains of K-RAS do
not predict resistance, as most recent data has shown (Khambata-
Ford et al., 2007; De Roock et al., 2010). Also, activating mutations
further downstream, in BRAF, or in an alternative and parallel
pathway, PI3Kinase, may also select tumors that are unrespon-
sive to anti-EGFR antibodies (Sartore-Bianchi et al., 2009; Berg
www.frontiersin.org October 2011 | Volume 2 | Article 59 | 3
Batist et al. Resistance to cancer treatment
et al., 2010), although the evidence is so far not clinically validated
since these antibodies are generally given togetherwith chemother-
apy, making it difﬁcult to identify resistance speciﬁcally to the
antibody.
While still generally considered non-speciﬁc compared to
newer“targeted agents,” a strong case can be made that many cyto-
toxic drugs exert their anti-tumor effect through speciﬁc or a ﬁnite
number of molecular targets, just as targeted agents often mod-
ulate more than one molecule. The role of DNA repair genes in
effecting resistance to DNA damaging agents such as cisplatin has
been highlighted above. Some targets of cytotoxic drugs include
tubulin components in the case of taxanes or vinca alkaloids, a
speciﬁc topoisomerase isoform for doxorubicin, etc. Experimen-
tal models have pointed to a variety of explanations for resistance
that have focused on cell survival and detoxiﬁcation as opposed to
alterations in the targets. Clinical studies have not conﬁrmed that
modifying any single one of these can overcome resistance. More
recently attention has turned to master transcription factor called
Nuclear factor erythroid-2 related factor-2 (Nrf2), which regu-
lates a cytoprotective gene program that includes a large number
of thesemechanisms. The level of Nrf2 protein available to translo-
cate to the nuclear and activate the program is regulated through
its physical interaction with Klech-like ECH-associated protein 1
(Keap1), which functions as an adapter protein that targets Nrf2
to Cullin 3 ubiquitin E3 ligase (Cul3), and the proteosome for
degradation (Loignon et al., 2009). Some sub-types of the gen-
erally chemo-resistant NSCLC, cell lines and clinical specimens,
have been found to frequently possess one of a restricted num-
ber of loss-of-function somatic mutations in Keap1, which results
in constitutively high levels of Nrf2 along with the cell protective
proteins it regulates (Singh et al., 2006). Depletion of Nrf2, using
siRNA or with small chemical molecules, results in dramatic sensi-
tization of these cells to clinically relevant cytotoxics (Singh et al.,
2008; Ren et al., 2011).
These are some examples of the challenge of identifying, val-
idating and responding to clinical resistance to cancer therapies.
Since they are frequently due to somatic genetic events in the
tumor, they can be addressed in a fairly selective manner. There
are a number of critical points to emphasize. A major challenge in
identifying for study mechanisms of resistance to drugs that devel-
ops in the metastatic setting is ensuring that we examine the actual
tissue that is clinically resistant; this of course requires biopsy of
metastatic tumors at the start of therapy and at the advent of thera-
peutic resistance, with some assumption that tumor heterogeneity
does not play a major role in secondary resistance. Although this
represents both logistical and ethical challenges, we and others
have successfully overcome them (Batist et al., 2010; Hilton et al.,
2010). Tissue must be obtained in a manner that reliably preserves
nucleic acids and morphology, and can be validated to be com-
posed of at least “predominantly” tumor. An important challenge
is to maintain control of both data and tissue sample ﬂow, par-
ticularly when linking multiple clinical sites to major technology
platforms. This is critical to preserve enoughmaterial for a range of
analyses. To enhance the efﬁcacy of analytical testing, it is critical to
develop tumor type-speciﬁc multiplex tests that can be performed
on minimal material in a CLIA-standard laboratory with a very
strong program of quality control. Each multiplex technology has
its own limits, and it is therefore crucial that rigorous qualiﬁca-
tion processes and external quality controls are in place. A good
example in the literature is the Quebec-wide process for colon
cancer-orientedmultiplex ligation-dependent probe ampliﬁcation
(Jarry et al., 2011).
The data reviewed in these examples indicate the requirement
for the development of next generation targeting agents that can
overcome mechanisms of resistance caused by mutations in the
target, and furthermore, that combinations of targeted agents will
ultimately be necessary to anticipate and overcome therapeutic
resistance related to non-target genes. Closer links between the
clinic, molecular proﬁling expertise and mechanistic laboratories
are essential to sort out which of the many somatic genetic events
found in a given tumor is driving the tumor growth, which are
potential escape paths that can become mechanisms of resistance
and which are merely passengers with no immediate reason to
target.
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